Nivalis Therapeutics (NVLS) Reports Q3 Loss of $0.39/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts NVLS Hot Sheet
Price: $2.40 --0%
Financial Fact:
Research and development: 49.15M
Today's EPS Names:
CCEL, MHGU, NRIX, More
Financial Fact:
Research and development: 49.15M
Today's EPS Names:
CCEL, MHGU, NRIX, More
Join SI Premium – FREE
Nivalis Therapeutics (NASDAQ: NVLS) reported Q3 EPS of ($0.39), versus ($7.68) reported last year.
For earnings history and earnings-related data on Nivalis Therapeutics (NVLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- JPMorgan Downgrades DSV A/S (DSV:DC) (DSDVF) to Neutral
- Truist Securities Starts IBM (IBM) at Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
